40 results about "Transplant recipient" patented technology

Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab. Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.

The invention provides a precise monitoring and self-adaptive regulation and control system for immunological rejection in solid organ transplantation. Relates to the field of artificial intelligence, and the system comprises a real-time data collection module which is used for collecting rejection-related biomarkers, organ function data and environment and treatment data in peripheral blood of a transplanted recipient in real time; the rejection risk prediction module is used for processing multi-dimensional time sequence characteristic data acquired in real time by adopting a long-short term memory network rejection risk prediction model based on layered boundary marginal loss function optimization, and outputting a rejection risk probability P; the intervention strategy generation module is used for generating an individualized intervention strategy through a mixed mask neighbor strategy optimization algorithm according to the current pathological state of the patient; and the intelligent decision regulation and control module is used for executing regulation and control decisions of precise regulation and control of the immunosuppressor and coordinated regulation and control of the organ microenvironment according to the rejection risk probability P and the individualized intervention strategy and performing real-time feedback. The rejection reaction recognition accuracy and intervention effectiveness are improved.

This invention relates to the field of medical technology, specifically to a method for preoperative risk assessment and prediction in liver transplant patients with hepatocellular carcinoma, comprising the following steps: Sample collection: selecting plasma samples and corresponding clinicopathological information from liver transplant recipients of hepatocellular carcinoma, and clarifying the inclusion and exclusion criteria for samples; Plasma cell-free DNA extraction and whole-genome sequencing: extracting and quality-controlling cell-free DNA from the plasma samples collected in step S1, constructing a sequencing library, and performing low-coverage whole-genome sequencing. This invention utilizes plasma-extracted cfDNA for whole-genome sequencing, combined with clinical testing information, to construct a preoperative risk assessment and prediction model for postoperative recurrence in liver transplant recipients of hepatocellular carcinoma based on non-invasive testing. This model can be used to predict the probability of recurrence-free survival before liver transplantation. The model derivation cohort integrates clinical records and circulating tumor DNA data for preoperative recurrence risk prediction.

The invention provides a method for determining the content of an anti-SLA antibody in swine xenograft receptor serum, and belongs to the technical field of biology. The method comprises the following steps: respectively incubating swine xenograft receptor serum, SLA-knocked-out swine PBMC and SLA-unknocked-out swine PBMC by utilizing the difference between swine PBMC surface xenoantigen and swine RBC surface xenoantigen, detecting antibody combination, and calculating a flow type difference value to obtain the anti-SLA antibody content in the swine xenograft receptor serum. When a heterologous kidney transplantation recipient has a rejection reaction, the method provided by the invention can effectively and quickly determine whether the rejection reaction is caused by the SLA antigen, so that targeted treatment is performed, and effective control of the rejection reaction of the heterologous recipient is facilitated.

This invention provides a pharmaceutical composition for use in a method of preventing antibody-mediated rejection (ABMR) in subjects who have undergone solid organ transplantation by preventing complement activity. [Solution] A pharmaceutical composition comprising an anti-human interleukin-6 (IL-6) antibody or an anti-human IL-6 antibody fragment for use in a method of preventing, stabilizing, or reducing complement activity in a subject who is scheduled to receive, has received, or has received a solid organ transplant, wherein the method comprises administering to a subject a prophylactic or therapeutically effective amount of the antibody or antibody fragment, the pharmaceutical composition comprising a variable light chain polypeptide containing a CDR of a specific sequence, and a variable heavy chain polypeptide containing a CDR of a specific sequence.

The present disclosure relates to ready-to-use, surfactant free, oral, aqueous suspension formulations comprising one or more immunosuppressive agents. The ready-to-use suspension formulations of the present disclosure can be useful in treating organ or stem cell transplant recipients or T-cell mediated diseases.

The invention relates to the technical field of medicine, and discloses a transcriptomics-based prognosis prediction model for a super-aglaia standard hepatocellular carcinoma liver transplantation recipient. The prognosis prediction model comprises the steps of standardized sample collection and quality control, standardized RNA-seq library construction and sequencing, data preprocessing and quality control, pathway activity feature extraction, molecular typing model construction, prognosis verification and clinical application. The method can deeply understand the heterogeneity and prognosis of liver cancer liver transplantation recipients, the recipients are divided into different subgroups by analyzing gene expression modes in tumor tissues, an important basis is provided for prognosis evaluation of the recipients, key genes with different expression levels in different subgroups can be identified, a more accurate scheme is provided for individualized treatment, and the method is suitable for popularization and application. The RNA-seq-based molecular typing model provides a comprehensive, accurate and individualized method for prognosis evaluation of standard liver cancer liver transplantation recipients of the super-aglaia, and is helpful for improving clinical outcomes of patients.

Disclosed herein are methods for diagnostic tools to calculate the risk of acute rejection in a renal allograft recipient.

The invention belongs to the technical field of biology, and particularly relates to a pharmaceutical composition for inducing gonad exhaustion of paralichthys olivaceus and application of the pharmaceutical composition. The pharmaceutical composition comprises docetaxel and cis-platinum, the mass ratio of docetaxel to cis-platinum is 1: 1, and the total concentration of docetaxel and cis-platinum is 100-200 mu g / mL. By optimizing the medicine proportion and the administration scheme, the problems of low survival rate and large injury of fish bodies in the existing gonad exhaustion method are solved, and efficient and stable preparation of the paralichthys olivaceus germline stem cell transplantation receptor can be realized. By controlling the ratio of docetaxel to cis-platinum, the administration concentration, the injection frequency, the action period and the like, the invention aims to solve the problems of insufficient exhaustion effect, low fish survival rate or serious gonad injury and the like in the existing receptor preparation, and provides reliable technical support for establishing a stable and efficient paralichthys olivaceus germline stem cell transplantation receptor system.

The invention provides a digital PCR (polymerase chain reaction) detection system for detecting the proportion of donor-derived free DNA (deoxyribonucleic acid) in an organ transplantation recipient and application thereof, the system is used for detecting one or more of diallelic SNP (single nucleotide polymorphism) sites, and a pair of universal primers and a specific probe crossing the diallelic SNP sites are used when each diallelic SNP site is detected, the specific probe is used for detecting the diallelic SNP site, the probe is completely complementarily matched with a section of sequence in a wild type template or a mutant type template of the diallelic SNP site, and correspondingly, the probe is not completely complementarily matched with a section of sequence of another template. By means of the system, accurate quantification of target nucleic acid can be achieved under the background of a complex sample.

Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in solid organ transplant recipients, such as pancreatic transplant recipients, pancreatic and kidney transplant recipients, and simultaneous pancreatic and kidney transplant recipients. Methods described herein may involve combined assessment of blood gene expression profiles from an assessment of particular, related mRNA transcript levels and donor-derived cell-free nucleic acids (dd-cfDNA) or each an independent assessment of the mRNA transcript level as well as an independent assessment of the dd-cfDNA. Genes that correlate with pancreatic transplant rejection in simultaneous pancreatic and kidney transplant recipients are also disclosed.

In certain embodiments, the present invention provides methods of identifying and treating a transplant recipient patient having transplantation tolerance induced by apoptotic donor leukocytes infused under cover of transient immunotherapy.

The invention features compositions and methods for treating transplant recipients (e.g., chronic allograft rejection) using a senolytic agent and an angiotensin II receptor antagonist or using a senolytic agent and senomorphic agent. The methods and compositions are useful in a variety of transplant settings including, without limitation, solid organ transplants including kidney, lung, heart, liver, intestine, or pancreas transplantation procedures and cellular transplants including but not limited to bone marrow transplants.

The present invention relates to a method for predicting the outcome of liver transplantation for the treatment of hepatocellular carcinoma (HCC), or a method for arranging HCC patients to receive liver transplantation, comprising the following steps: determining the expression levels of indicator genes (including skin pontin, clusterin, calpain small subunit 1, F-box and WD repeat protein 7 and SproutyRTK signaling antagonist 2) selected from liver samples of patients suffering from HCC, and comparing the expression levels of the indicator genes with the expression levels of internal reference genes, and combining this with the variable total tumor volume through a linear support vector machine algorithm to predict a good prognosis for the liver transplant recipient.

The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

The invention provides a kidney transplantation recipient health management platform system based on digital therapy, which comprises a digital target point unit, a data analysis module, a digital library and a treatment module, the digital target point unit is used for acquiring acquired data, the data analysis module is used for acquiring the acquired data uploaded by the digital target point unit, and the treatment module is used for treating the acquired data. Analyzing and modeling the acquired data to form a recipient model; the digital library is a cloud data center, the digital library is in communication connection with the data analysis module, and the digital library is used for comparing the recipient model with the medical information data to obtain reference data; and the treatment module obtains the reference data, formulates a corresponding treatment scheme and provides the treatment scheme to a transplantation recipient.

The present invention relates to the use of mesenchymal stem cells to reduce inflammation and immune responses for neuromuscular injuries and limb transplants. A particular preferred embodiment relates to use of mesenchymal stem cells that are modified to express interleukin-10 in limb transplantation surgery. In particular embodiments, the present invention also provides a method of improving nerve and muscle regeneration and functional outcome for limb transplantation in a mammalian limb transplant recipient by administering to the limb transplant recipient a therapeutic amount of mesenchymal stem cells.

New methods for assessing the status of transplant rejection in transplant recipients, such as kidney transplant recipients, are disclosed. The diagnostic methods utilize the measurement of TCR subunit repertoire diversity to identify stable subjects, subjects undergoing cell-mediated rejection processes, and subjects undergoing antibody-mediated rejection processes. The proportion of unique TCR alpha and beta subunit sequences to the total unique TCR subunit sequences (total sequences of alpha, beta, delta, and gamma subunits) provides a diagnostic measure that can identify stable subjects, subjects undergoing cell-mediated rejection processes, and subjects undergoing antibody-mediated rejection processes. If antibody-mediated rejection or cell-mediated rejection is detected, treatment methods include administration of appropriate therapy.

The invention discloses application of a cytokine LYG1 in preparation of a medicine for promoting immune reconstruction after hematopoietic stem cell transplantation. The invention further discloses a medicine for promoting immune reconstitution after hematopoietic stem cell transplantation. The medicinal ingredient of the medicine is the cytokine LYG1. A large number of tests prove that the LYG1 deficiency can obviously inhibit immune reconstruction after hematopoietic stem cell transplantation, and the influence of the LYG1 deficiency of a recipient on the immune reconstruction after hematopoietic stem cell transplantation is more obvious. Therefore, the LYG1 treatment is given to a transplantation recipient, namely a patient, so that the immune reconstitution of the patient can be accelerated.

The present disclosure is related to compositions and systems for inducing immune tolerance for transplanted cells, organ, or tissues in a transplant recipient. Also provided herein are methods of making and methods of administering tolerizing vaccines / regimen or preparatory regimens.

The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

The present disclosure relates to products and methods relating to transplant recipient antibodies bound to donor cell membrane fragments. Products and methods provided are used to separate and collect transplant recipient antibodies from donor cell membrane fragments, as well as to characterize the transplant recipient antibodies. The products and methods are useful for allotransplant or xenotransplant recipients.

Disclosed herein are computer-implemented systems, kits, and methods for determining an amount of contributor-derived nucleic acids in a biological sample, from a transplant recipient, that comprises nucleic acids from two or more genetically distinct contributors. The determined amount of contributor-derived nucleic acids may be useful in monitoring the status of a transplant for, e.g., assessing a risk of transplant rejection. In some examples, the two or more genetically distinct contributors may comprise the transplant recipient, fetus, and transplant donor. In some examples, the two or more genetically distinct contributors may comprise the transplant recipient, first transplant donor, and second transplant donor. For example, the systems and methods determine an estimated percentage of the contributor-derived nucleic acids and / or estimated percentage of the fetal-derived nucleic acids.

Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and / or therapeutic immunotherapies based on cytotoxic T cell (CTL)-recognized T cell epitopes (e.g., CMV epitopes), and can be used to prevent and / or treat CMV infection, reactivation, and / or disease (e.g., CMV-associated end-organ disease), especially in solid organ transplant recipients.

Disclosed are methods for evaluating genetic models that are predictive of autoimmune disease phenotype or status. The methods comprise obtaining genotype data from bone marrow transplant recipients and donors. The autoimmune disease phenotype of the transplant recipient after the transplantation may be used evaluate the effect of genotype on the autoimmune disease. Phenotype comparisons may be made to the transplant donor and / or the transplant recipient prior to the transplantation. The methods may be used to validate genetic models associated with autoimmune disease. The genetic models may be based on one or more genetic variants associated with susceptibility to or protection from an autoimmune disease.

Disclosed herein are computer-implemented systems, kits, and methods for outputting an amount of contributor-derived nucleic acids in a biological sample, from a pregnant transplant recipient, that comprises nucleic acids from at least three genetically distinct contributors. The amount of contributor-derived nucleic acids may be useful in monitoring the status of a transplant for, e.g., assessing a risk of transplant rejection. In some examples, the at least three genetically distinct contributors may comprise a maternal genomic contributor, a fetal genomic contributor, and a transplant donor genomic contributor. For example, the systems and methods determine an estimated percentage of the contributor-derived nucleic acids and / or estimated percentage of the fetal-derived nucleic acids.

The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

The invention relates to biomarker signatures for stratifying the graft function and / or infection status of a solid organ transplant recipient, methods of using the same and kits for the detection thereof. In particular, the present invention relates to biomarker signatures for stratifying Chronic Lung Allograft Dysfunction (CLAD) and / or infection status of a lung transplant recipient.

Disclosed herein are computer-implemented systems, kits, and methods for outputting an amount of contributor-derived nucleic acids in a biological sample, from a transplant recipient who has received at least two transplants, that comprises nucleic acids from at least three genetically distinct contributors. The amount of contributor-derived nucleic acids may be useful in monitoring the status of a transplant for, e.g., assessing a risk of transplant rejection. In some examples, the at least three genetically distinct contributors may comprise a recipient genomic contributor, a first transplant donor genomic contributor, and a second transplant donor genomic contributor. For example, the systems and methods determine an estimated percentage of the contributor-derived nucleic acids and / or estimated percentage of the fetal-derived nucleic acids.